Table 1 Baseline characteristics of the Taiwanese population in the GLOBE trial, 2303 study, and HBV DNA kinetics analysis
Characteristic | GLOBE trial | Study 2303 | HBV DNA reduction kinetics study HBeAg-positive patients from GLOBE | ||||
|---|---|---|---|---|---|---|---|
HBeAg- positive (n = 16) | HBeAg- negative (n = 25) | HBeAg- positive (n = 16) | HBeAg- negative (n = 25) | ≤5 log10 copies/mL at Week 24 (n = 8) | >5 log10 copies/mL at Week 24 (n = 26) | P value | |
Age (years) | |||||||
Median (min–max) | 27.5 (19–53) | 45.0 (20–63) | 29.5 (21–55) | 47.0 (22–65) | 38.0 (20–45) | 27.5 (19–56) | |
Age range, n (%) | |||||||
<30 | 9 (56.3) | 1 (4.0) | 8 (50.0) | 1 (4.0) | 3 (37.5) | 15 (57.7) | |
30–50 | 6 (37.5) | 19 (76.0) | 7 (43.8) | 17 (68.0) | 5 (62.5) | 8 (30.8) | 0.223 |
>50 | 1 (6.3) | 5 (20.0) | 1 (6.3) | 7 (28.0) | 0 (0) | 3 (11.5) | |
Gender | |||||||
Male, n(%) | 11 (68.8) | 21 (84.0) | 11 (68.8) | 21 (84.0) | 5 (62.5) | 19 (73.1) | 0.566 |
Female, n(%) | 5 (31.3) | 4 (16.0) | 5 (31.3) | 4 (16.0) | 3 (37.5) | 7 (26.9) | |
Weight | |||||||
Median (min–max) | 67.5 (48–95) | 68.0 (42–95) | 69.5 (51–92) | 65.5 (43–91) | 61.5 (49–73) | 67.5 (38–95) | |
HBV genotype, n(%) | |||||||
B | 13 (81.3) | 17 (68.0) | 13 (81.3) | 17 (68.0) | 5 (62.5) | 16 (61.5) | |
C | 3 (18.8) | 8 (32.0) | 3 (18.8) | 8 (32.0) | 3 (37.5) | 10 (38.5) | 0.961 |
HBV DNA (log 10 copies/mL) | |||||||
Median (min–max) | 10.2 (7–13) | 7.2 (4–13) | 2.5 (2–10) | 2.2 (2–5) | 8.9 (6–10) | 10.2 (8–15) | |
ALT (U/L) | |||||||
Median (min–max) | 134.5 (51–288) | 110.0 (40–499) | 27.5 (10–272) | 29.0 (15–63) | 92.0 (53–231) | 149.0 (43–767) | |